¢¸
  • È«¿ª¿¹¹æÁ¢Á¾ÈÄ ¿¬·É Áõ°¡¿¡ µû¸¥ Ç÷û³» È«¿ª ƯÀÌ IgGÀÇ º¯µ¿   (1 ÆäÀÌÁö)
    1

  • È«¿ª¿¹¹æÁ¢Á¾ÈÄ ¿¬·É Áõ°¡¿¡ µû¸¥ Ç÷û³» È«¿ª ƯÀÌ IgGÀÇ º¯µ¿   (2 ÆäÀÌÁö)
    2

  • È«¿ª¿¹¹æÁ¢Á¾ÈÄ ¿¬·É Áõ°¡¿¡ µû¸¥ Ç÷û³» È«¿ª ƯÀÌ IgGÀÇ º¯µ¿   (3 ÆäÀÌÁö)
    3

  • È«¿ª¿¹¹æÁ¢Á¾ÈÄ ¿¬·É Áõ°¡¿¡ µû¸¥ Ç÷û³» È«¿ª ƯÀÌ IgGÀÇ º¯µ¿   (4 ÆäÀÌÁö)
    4

  • È«¿ª¿¹¹æÁ¢Á¾ÈÄ ¿¬·É Áõ°¡¿¡ µû¸¥ Ç÷û³» È«¿ª ƯÀÌ IgGÀÇ º¯µ¿   (5 ÆäÀÌÁö)
    5

  • È«¿ª¿¹¹æÁ¢Á¾ÈÄ ¿¬·É Áõ°¡¿¡ µû¸¥ Ç÷û³» È«¿ª ƯÀÌ IgGÀÇ º¯µ¿   (6 ÆäÀÌÁö)
    6

  • È«¿ª¿¹¹æÁ¢Á¾ÈÄ ¿¬·É Áõ°¡¿¡ µû¸¥ Ç÷û³» È«¿ª ƯÀÌ IgGÀÇ º¯µ¿   (7 ÆäÀÌÁö)
    7

  • È«¿ª¿¹¹æÁ¢Á¾ÈÄ ¿¬·É Áõ°¡¿¡ µû¸¥ Ç÷û³» È«¿ª ƯÀÌ IgGÀÇ º¯µ¿   (8 ÆäÀÌÁö)
    8

  • È«¿ª¿¹¹æÁ¢Á¾ÈÄ ¿¬·É Áõ°¡¿¡ µû¸¥ Ç÷û³» È«¿ª ƯÀÌ IgGÀÇ º¯µ¿   (9 ÆäÀÌÁö)
    9

  • È«¿ª¿¹¹æÁ¢Á¾ÈÄ ¿¬·É Áõ°¡¿¡ µû¸¥ Ç÷û³» È«¿ª ƯÀÌ IgGÀÇ º¯µ¿   (10 ÆäÀÌÁö)
    10

  • È«¿ª¿¹¹æÁ¢Á¾ÈÄ ¿¬·É Áõ°¡¿¡ µû¸¥ Ç÷û³» È«¿ª ƯÀÌ IgGÀÇ º¯µ¿   (11 ÆäÀÌÁö)
    11


  • º» ¹®¼­ÀÇ
    ¹Ì¸®º¸±â´Â
    11 Pg ±îÁö¸¸
    °¡´ÉÇÕ´Ï´Ù.
¢º
Ŭ¸¯ : ´õ Å©°Ôº¸±â
  • È«¿ª¿¹¹æÁ¢Á¾ÈÄ ¿¬·É Áõ°¡¿¡ µû¸¥ Ç÷û³» È«¿ª ƯÀÌ IgGÀÇ º¯µ¿   (1 ÆäÀÌÁö)
    1

  • È«¿ª¿¹¹æÁ¢Á¾ÈÄ ¿¬·É Áõ°¡¿¡ µû¸¥ Ç÷û³» È«¿ª ƯÀÌ IgGÀÇ º¯µ¿   (2 ÆäÀÌÁö)
    2

  • È«¿ª¿¹¹æÁ¢Á¾ÈÄ ¿¬·É Áõ°¡¿¡ µû¸¥ Ç÷û³» È«¿ª ƯÀÌ IgGÀÇ º¯µ¿   (3 ÆäÀÌÁö)
    3

  • È«¿ª¿¹¹æÁ¢Á¾ÈÄ ¿¬·É Áõ°¡¿¡ µû¸¥ Ç÷û³» È«¿ª ƯÀÌ IgGÀÇ º¯µ¿   (4 ÆäÀÌÁö)
    4

  • È«¿ª¿¹¹æÁ¢Á¾ÈÄ ¿¬·É Áõ°¡¿¡ µû¸¥ Ç÷û³» È«¿ª ƯÀÌ IgGÀÇ º¯µ¿   (5 ÆäÀÌÁö)
    5

  • È«¿ª¿¹¹æÁ¢Á¾ÈÄ ¿¬·É Áõ°¡¿¡ µû¸¥ Ç÷û³» È«¿ª ƯÀÌ IgGÀÇ º¯µ¿   (6 ÆäÀÌÁö)
    6

  • È«¿ª¿¹¹æÁ¢Á¾ÈÄ ¿¬·É Áõ°¡¿¡ µû¸¥ Ç÷û³» È«¿ª ƯÀÌ IgGÀÇ º¯µ¿   (7 ÆäÀÌÁö)
    7

  • È«¿ª¿¹¹æÁ¢Á¾ÈÄ ¿¬·É Áõ°¡¿¡ µû¸¥ Ç÷û³» È«¿ª ƯÀÌ IgGÀÇ º¯µ¿   (8 ÆäÀÌÁö)
    8

  • È«¿ª¿¹¹æÁ¢Á¾ÈÄ ¿¬·É Áõ°¡¿¡ µû¸¥ Ç÷û³» È«¿ª ƯÀÌ IgGÀÇ º¯µ¿   (9 ÆäÀÌÁö)
    9

  • È«¿ª¿¹¹æÁ¢Á¾ÈÄ ¿¬·É Áõ°¡¿¡ µû¸¥ Ç÷û³» È«¿ª ƯÀÌ IgGÀÇ º¯µ¿   (10 ÆäÀÌÁö)
    10



  • º» ¹®¼­ÀÇ
    (Å« À̹ÌÁö)
    ¹Ì¸®º¸±â´Â
    10 Page ±îÁö¸¸
    °¡´ÉÇÕ´Ï´Ù.
´õºíŬ¸¯ : ´Ý±â
X ´Ý±â
µå·¡±× : Á¿ìÀ̵¿

È«¿ª¿¹¹æÁ¢Á¾ÈÄ ¿¬·É Áõ°¡¿¡ µû¸¥ Ç÷û³» È«¿ª ƯÀÌ IgGÀÇ º¯µ¿

·¹Æ÷Æ® > Àι®»çȸ ÀÎ ¼â ¹Ù·Î°¡±âÀúÀå
Áñ°Üã±â
Å°º¸µå¸¦ ´­·¯ÁÖ¼¼¿ä
( Ctrl + D )
¸µÅ©º¹»ç
Ŭ¸³º¸µå¿¡ º¹»ç µÇ¾ú½À´Ï´Ù.
¿øÇÏ´Â °÷¿¡ ºÙÇô³Ö±â Çϼ¼¿ä
( Ctrl + V )
ÆÄÀÏ : È«¿ª¿¹¹æÁ¢Á¾ÈÄ ¿¬·É Áõ°¡¿¡ µû¸¥ Ç÷û³» È«¿ª ƯÀÌ I~.hwp   [Size : 70 Kbyte ]
ºÐ·®   11 Page
°¡°Ý  1,500 ¿ø

Ä«Ä«¿À ID·Î
´Ù¿î ¹Þ±â
±¸±Û ID·Î
´Ù¿î ¹Þ±â
ÆäÀ̽ººÏ ID·Î
´Ù¿î ¹Þ±â


ÀÚ·á¼³¸í
¹é½ÅÀÇ Á¢Á¾ÈÄ ¹æ¾îÈ¿°ú ±â°£¿¡ ´ëÇÑ ¿¬±¸¿¡¼­ Brown µî22)Àº Á¢Á¾ ÈÄ Ç÷û¾çÀüÀ» È®ÀÎÇÑ 136¸í °¡¿îµ¥ 95%(129¸í)°¡ 5³âÈÄ¿¡µµ °è¼Ó...
º»¹®/³»¿ë
¹é½ÅÀÇ Á¢Á¾ÈÄ ¹æ¾îÈ¿°ú ±â°£¿¡ ´ëÇÑ ¿¬±¸¿¡¼­ Brown µî22)Àº Á¢Á¾ ÈÄ Ç÷û¾çÀüÀ» È®ÀÎÇÑ 136¸í °¡¿îµ¥ 95%(129¸í)°¡ 5³âÈÄ¿¡µµ °è¼Ó Ç×ü ¾ç¼ºÀ» º¸ÀÌ°í ÀÖ´Ù°í ÇÏ¿´°í, Krugman23)Àº ¹é½Å Á¢Á¾ ÈÄ Ç÷û¾çÀüµÇ¾ú´ø ¼Ò¾ÆµéÁß ÀÏ¹Ý °¡Á¤ÀÇ ¾Æµ¿Àº 14³âÈÄ 99%(98/99)°¡ °è¼Ó Ç×ü ¾ç¼­À̾ú°í ¼ö¿ë½Ã¼³(°í¾Æ¿ø) ¾Æµ¿Àº 91%(71/78)°¡ ¾ç¼ºÀ̾ú´Âµ¥ ¼ö¿ë½Ã¼³ ¾Æµ¿¿¡¼­ ¾ç¼ºÀ²ÀÌ ³·Àº ÀÌÀ¯´Â ±×µéÀÌ ÀÚ¿¬ È«¿ª¿¡ÀÇ Á¢Ã˱âȸ°¡ Àû¾î¼­ ¸é¿ª°­È­È¿°ú°¡ Àû¾ú±â ¶§¹®À̶ó°í ÇÏ¿´´Ù. 16³â°£ ÃßÀûÀÌ °¡´ÉÇß´ø ¼ö¿ë½Ã¼³ ¾Æµ¿ÀÇ °æ¿ì 16³âÈÄ Ç×ü ¾ç¼ºÀ²Àº 87%(61/70)¿´À¸¸ç, HI°Ë»ç ¿ª°¡´Â Á¢Á¾ÈÄ Æò±Õ 1:333¿¡¼­ 16³âÈÄ 1:6À¸·Î °¨¼ÒµÇ¾ú°í È«¿ªÀ» ¾ÎÀº ¾Æµ¿µéÀº 1:410¿¡¼­ 1:22·Î °¨¼ÒÇÏ¿© È«¿ªÀ» ¾ÎÀº °æ¿ìÀÇ Ç×ü°¡°¡ ´õ ³ô¾Ò´Ù. Miller24)´Â È«¿ª¹é½Å Á¢Á¾ÀÚ 4,500·Ê¿¡ ´ëÇÑ 21³â°£ÀÇ ÃßÀûÁ¶»ç¿¡¼­ Á¢Á¾ÈÄ Ãʱâ 5³â°£ ¹æ¾îÀ²ÀÌ 91%·Î ³ªÅ¸³µÀ¸¸ç ±×ÈÄ¿¡´Â 0.5/1,000¸íÀÇ ¸Å¿ì ³·Àº ¹ß»ýºóµµ¸¦ º¸¿© °è¼ÓÀûÀ¸·Î Ç×ü°¡°¡ ¹æ¾î¼öÁØ ÀÌ»óÀ¸·Î Àß À¯ÁöµÇ¾ú´Ù°í º¸°íÇÏ¿´À¸¸ç, Markowitz µî25)°ú Hullµî26)Àº ¹é½Å Á¢Á¾ÈÄ ½Ã°£ÀÇ °æ°ú¿¡ µû¶ó ¹é½Å½ÇÆа¡ Áõ°¡µÇÁö´Â ¾ÊÀ¸¸ç ÀÌÂ÷ ¹é½Å½ÇÆа¡¡¦(»ý·«)
Âü°í¹®Çå
1) Markowitz LE, Orenstein WA: Measles Vaccines. Pediatr Clin North Am 37:603-649, 1990
2) Rosenthal SR, Clements CJ: Two dose measles vaccination schedules. Bull WHO 71:421-428, 1993
3) Hopkins DR, Hinman AR, Koplan JP, Lane JM: The case for global measles eradication. Lancet 6:1396-1398, 1982
4) º¸°Ç »çȸºÎ: Á¦2Á¾ ÁÖ¿ä Àü¿°º´ ÀÌȯÀ². º¸°Ç»çȸÅë°è¿¬º¸. 1990 p16-17
5) º¸°Ç »çȸºÎ: Á¦2Á¾ ÁÖ¿ä Àü¿°º´ ÀÌȯÀ². º¸°Ç»çȸÅë°è¿¬º¸. 1994 p18-19
6) ±¹¸³º¸°Ç¿ø: Á¦1, 2Á¾ ¹ýÁ¤Àü¿°º´ÀÇ ¿ù°£ ±¹³» Åë°è. °¨¿°º´¹ß»ýÁ¤º¸ 6:33, 1995
7) ¼Õ¿µ¸ð, ȫâȣ, À̽±Ô: ÃÖ±Ù ¼­¿ï °­³²Áö¿ª¿¡¼­ À¯ÇàÇÑ È«¿ªÀÇ ¹ß»ý ¾ç»ó, 1989-1990. ´ëÇÑÀÇÇÐÇùȸÁö 34:960-968, 1991
8) À̱ÝÀÚ, ÀÌ°ÇÈñ À±Çý¼±: È«¿ª Ç×ü°¡ ÃøÁ¤¿¡ ÀÇÇÑ È«¿ª ¿¹¹æ ¹é½ÅÀÇ Á¢Á¾ ½Ã±â¿Í È¿°ú¿¡ °üÇÑ ¿¬±¸. ¼Ò¾Æ°ú 34:1201-1210, 1991
9) ÃÖ»ó¹¬, ¿Àâ¼ö, ¹Ú»óö, ±èâÈÖ, ÀÌ»óÁÖ: Ç÷ûÇÐÀûÀ¸·Î Áø´ÜµÈ È«¿ª¿¡ ´ëÇÑ °íÂû. ¼Ò¾Æ°ú 35:508-514, 1992
10) Kim SK, Son BK, Chung CY, Ahn YM, Park CY, Lee HJ: Efficcy of measles vaccine during the 1993 measles epidemic in korea Pediatr Infect Dis J 14:346-349, 1995
11) ¼ÛÀ±¹Ì, À̽ÂÈÆ, ¼­È«°ü, ȲÀÎÈ«, ÇãºÀ¿­, ÀÓÇö¼ú: ÀϺΠµµ½ÃÁö¿ª¿¡¼­ÀÇ È«¿ª ¹ß»ý¿¡ °üÇÑ ¿ªÇÐÁ¶»ç. °¡Á¤ÀÇ 11:20-29, 1990
12) ´ëÇѼҾưúÇÐȸ °¨¿°À§¿øȸ, Ãֿ빬, ±èâÈÖ, ¼­Á¤±â, ¼Õ¿µ¸ð, ¿À¼ºÈñ, ÀÌȯÁ¾, ÀüÁ¤½Ä: ¿ì¸®³ª¶ó¿¡¼­ ÇöÀç ½ÃÇàµÇ°í ÀÖ´Â È«¿ª ¿¹¹æÁ¢Á¾¿¡ ´ëÇÑ ÀçÆò°¡. ¼Ò¾Æ°ú 34:435-440, 1991
13) ´ëÇѼҾưúÇÐȸ °¨¿°À§¿øȸ, ¼Õ¿µ¸ð, ±èâÈÖ, ¿À¼ºÈñ, ÀÌȯÁ¾, ¹ÚÁ¾¿µ, ÀüÁ¤½Ä, ½Å»ó¸¸: ÃÖ±ÙÀÇ È«¿ª À¯Çà¿¡ ´ëÇÑ °íÂû. ¼Ò¾Æ°ú 37:289-291, 1994
14) Reyes MA, Vorrero MF, Roa J, Bergonzoli G, Saravia NG: Measles vaccine failure after documented seroconversion. Pediatr Infect Dis J 6:848-851, 1987
15) Linnemann CC, Rotte TS, Schife GM, Youtsey JL: A seroepidemiologic study of a measles epidemic in a highly immunized populatin. Am J Epidemiol 95:238-246, 1972
16) Schluederberg A, Lamm SH, Landrigan PJ, Black FL: Measles immunity in children vaccinated before one year of age. Am J Epidemiol 97:402-409, 1973
17) Cherry JD, Feigin RD, Lobes LA, Hinthorn DR, Shackelford PG, Shirley RH, Lins RD, Choi SC: Urban measles in the vaccine ear. Clinical, epidemiologic, and serologic study. J Pediatr 81:2217-230, 1972
18) Linnemann CC, Hegg ME, Rotte TC, Phair JP, Schiff GM: Measles IgM response during reinfection of previously vaccinated children. J Pediatr 82:798-801, 1973
19) Mathias RG, Meekison WG, Arcand TA, Schechter MT: The role of secondary vaccine failure in measles outreakes. Am J Public Health 79:475-478, 1989
20) Edmonson MB, Addiss DG, McPherson JT, Berg JL, Circo SR, Davis JP: Mild measles and secondary vaccine failure during a sustained outbarake in a highly vaccinated population. JAMA 263:2467-2471, 1990
21) Ozanne G, D’Halewyn M: Secondary immune response in a vaccinated population during a large measles epidemic. J Clinic Micro 30:1778-1782, 1985
22) Brown P, Gajdusek DC, Tsai T: Persistence of measles antibody in the absence of circulating natural virus five years after immunization of an isolated virgin populations with Edmonston B vaccine. Am J Epidemiol 90:514-518, 1969
23) Krugman S: Present status of measles and rubella immunization in United States. A medical progress report. J Pediatr 90:1-12, 1977
24) Miller C: Live measles vaccine; a 21 year follow up. Br Med J 295:22-24, 1987
25) Markowitz LE, Sepulveda J, Diaz-Ortega JL, Valdespino JL, Albrecht P, Zell ER, Stewart J, Zarete ML, Bernier RH: Immunization of six-month old infants with different doses of Ed-monston-Zagreb and Schwarth measles vaccine. N Engl J Med 322:580-587, 1990
26) Hull HF, Montes JM, Hays PC, Lucero RL: Risk factors for measles vaccine failure among immunized students. Pediatrics 76:518-523, 1985
27) King JC, Lichestein R, Feigelman S, Luna C, Permutt TJ, Patel J: Measles, mumps, and rubella antibodies in vaccinated Baltimore children. Am J Dis Child 147:558-560, 1993
28) Â÷°æÈÆ, Á¤Àº°æ, ¹®°æ·¡, ±è°©½Â, ¹Ú»ó±â, ¹Ú¿µºÀ: È«¿ª¹é½Å Á¢Á¾ÈÄ Ç×ü°¡ÀÇ ¾çÀü·ü¿¡ °üÇÑ °íÂû. ¼Ò¾Æ°ú 34:1080-1085, 1991
29) ±è¹ÎÇý, ÀÌÁöÀº, ¼­Á¤¿Ï, È«¿µ¹Ì, ±è°æÈñ: ¼Ò¾Æ ¿¬·É¿¡ µû¸¥ È«¿ª Ç×ü°¡ÀÇ º¯µ¿¿¡ °üÇÑ ¿¬±¸. ¼Ò¾Æ°ú 34:1519-1525, 1991
30) Cutts FT, Markowitz LE: Successes and failure in measles control. J Infect Dis 170(Suppl 1): S32-41, 1994
31) Gustafson TL, Lievens AW, Brunell PA, Meollenberg RG, Christopher BS, Buttery MG, Sehulster SM: Measles outbreak in a fully immunized secondary-school population. N Engl J Med 316:771-774, 1987
32)
33) Markowitz LE, Albreit P, Orenstein WA, Lett SM, Pugliese TJ, Farrell D: Persistence of measles antibody after revaccination. J Infect Dis 166:205-208, 1992
34) Matson DO, Byington C, Canfield M, Albrecht P, Feign RD: Investigation of a measles outbrake in a fully vaccinated school population including serum studies before and after revaccination. Pediatr Infect Dis J 12:292-299, 1993
35) Cohn ML, Robinson ED, Faerber M, Thomas D, Geyer S, Peters S, Martin M, Martin A, Sobel D, Jones R, Larkin L, Richert JR: Measles vaccine failures: lack of sustained measles-specific immunoglobulin G responses in revaccinated adolescents and young adults. Pediatr Infect Dis J 13:34-38, 1994
36) Nkowane BM, Bart SW, Orenstein WA, Baltier M: Measles outbeak in a vaccinated school population: In previously vaccinated children. Am J Public Health 77:434-438, 1987
37) Orenstein WA, Albrecht P, Herrman KL, Bernier R, Bart KJ, Rovira EZ: Evaluation of low levels of measles antibody: the plaque neutralization test as a measure of prior exposure to measles virus. J Infect Dis 155:146-149, 1986
38) Hethcote HW, Measles and rubella in the United States. Am J Epidemiol 177:2-13, 1983
39) Hutchins Ss, Markowitz LE, Mead P, Mixon D, Sheline J, Greenberg N, Preblud SR, Orenstein WA, Hull HF: A school-based measles outbreak: The effect of a selective revaccination policy and risk factors for vaccine failure. Am J Epidemiol 132:157-168, 1990
40) Markowitz LE, Katz SL: Measles vaccine: In Plotkin SA, Mortimer EA Jr (Eds): Vaccine. 2 nd Ed. Philadelphia, WB Saunders Co, 1994 p229-276
41) Whittler RR, Veit BC, Mclntyre S, Schydlower M: Measles revaccination response in a school age populaton. Pediatrics 88:1024-1030, 1991


ÀÚ·áÁ¤º¸
ID : pigk*****
Regist : 2014-08-19
Update : 2014-08-19
FileNo : 16064448

Àå¹Ù±¸´Ï

¿¬°ü°Ë»ö(#)
È«¿ª¿¹¹æÁ¢Á¾ÈÄ   ¿¬·É   Áõ°¡¿¡   µû¸¥   Ç÷û³»   È«¿ª   IgG   º¯µ¿  


ȸ»ç¼Ò°³ | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æħ | °í°´¼¾ÅÍ ¤Ó olle@olleSoft.co.kr
¿Ã·¹¼ÒÇÁÆ® | »ç¾÷ÀÚ : 408-04-51642 ¤Ó ±¤ÁÖ±¤¿ª½Ã ±¤»ê±¸ ¹«Áø´ë·Î 326-6, 201È£ | äÈñÁØ | Åë½Å : ±¤»ê0561È£
Copyright¨Ï ¿Ã·¹¼ÒÇÁÆ® All rights reserved | Tel.070-8744-9518
ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æħ ¤Ó °í°´¼¾ÅÍ ¤Ó olle@olleSoft.co.kr
¿Ã·¹¼ÒÇÁÆ® | »ç¾÷ÀÚ : 408-04-51642 | Tel.070-8744-9518